Novel Thiazole Derivatives for Ulcerative Colitis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ulcerative colitis are inadequate in terms of efficacy and safety, with existing drugs exhibiting significant side effects and limited therapeutic progress over the years.
Innovation Solution
Development of novel thiazole derivatives with specific structural features, which are used to formulate a medicament for treating inflammatory bowel disease, particularly ulcerative colitis, through the creation of pharmaceutical compositions suitable for oral administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing drugs (aminosalicylic acid, sulfasalazine, oxarazin, mesalazine, immunosuppressive agents, hormonal drugs) are used for treating ulcerative colitis, then certain therapeutic effects are achieved, but serious side effects are produced
Solution Approach 1:
The patent applies parameter changes by developing novel thiazole derivative compounds with modified chemical structures (Formula I with specific R1-R4 substituents) to achieve different pharmacological properties compared to existing drugs. The structural modifications include varying the thiazole ring substituents and side chains to optimize therapeutic efficacy while reducing side effects
Solution Approach 2:
The patent employs composite materials by creating thiazole derivatives that combine multiple functional groups (aromatic rings, heterocyclic structures, amide bonds, and various substituents) into a single molecular framework. This composite molecular structure aims to achieve both therapeutic effectiveness and reduced toxicity
2Stability of the object's composition
If current treatments are continued for ulcerative colitis, then disease management is maintained, but there is no significant progress in treatment efficacy
Solution Approach 1:
The patent applies segmentation by dividing the treatment approach into distinct chemical series (Formula I with various R1-R4 combinations) to systematically explore structure-activity relationships. This segmented approach allows for methodical optimization of therapeutic efficacy while maintaining manageable disease control
Solution Approach 2:
The patent implements dynamics by developing a series of thiazole derivatives with varying substituent patterns that can be dynamically selected and optimized based on specific patient needs and disease severity. The flexible molecular framework allows for adaptation to different treatment requirements
Data Source
AI summary
The present invention relates to applications of a novel thiazole derivative in treating ulcerative colitis and in the preparation of drugs for treating ulcerative colitis. The present invention specifically relates to applications of a compound represented by formula I and a pharmaceutical composition containing the compound represented by formula I, in treating ulcerative colitis and in the preparation of drugs for treating ulcerative colitis: